AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC 2015
Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack. Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST